132 related articles for article (PubMed ID: 9612597)
21. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
22. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
23. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
24. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
25. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
27. [Phase I-II study of recombinant interferon gamma].
Adachi K; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Nakada H; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1331-8. PubMed ID: 2988459
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
29. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
Machida T; Koiso K; Takaku F; Ogawa M
Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Fisher RI; Rosenberg SA; Fyfe G
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S55-7. PubMed ID: 10685660
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
34. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
37. Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders.
Bolinger AM; Taeubel MA
Clin Pharm; 1992 Oct; 11(10):834-50; quiz 892-4. PubMed ID: 1341990
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
Huland E; Heinzer H; Huland H
Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
[TBL] [Abstract][Full Text] [Related]
39. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
Otto U; Schneider AW; Conrad S; Klosterhalfen H
Prog Clin Biol Res; 1990; 350():275-82. PubMed ID: 2117287
[No Abstract] [Full Text] [Related]
40. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
